Paxlovid associated with lower risk of hospital admission

PASADENA, Calif., March 16, 2023 /PRNewswire/ -- A Kaiser Permanente study confirms the benefit of nirmatrelvir-ritonavir, also known as Paxlovid, as an early-stage treatment to prevent hospitalization for people with mild to moderate COVID-19, regardless of prior immunity or age. The study was published March 15, 2023, in Lancet ID.